Integrate Study - C4C Recruitment | C4C

Many patients with schizophrenia smoke cannabis recreationally, a behaviour that is associated with an increased risk of relapse and more severe psychotic symptoms. The Integrate study will test whether a single dose of cannabidiol 1000mg can reduce the negative effects of acute cannabis intoxication in patients with schizophrenia. The study will be carried out at the Clinical Research Facility at King’s College Hospital. This project will identify patients who meet the study’s inclusion criteria to assist recruitment. Only patients who have provided consent for contact (C4C) will be contacted.